Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Date:11/9/2009

n attributable to the increase in cost of revenues relating to the write-up of acquired inventory to fair value; (iv) $11.8 million primarily relating to compensation-related charges associated with the Cytyc merger; and (v) a charge of $2.9 million related to impairment of acquired intangible assets.

Based on a combination of factors, including the deterioration in the macro-economic environment, declines in the stock market and the decline in the price of the Company's common stock, the Company experienced a significant decline in its market capitalization during the first quarter of fiscal 2009. As a result, the Company completed a goodwill impairment analysis as of December 27, 2008 using the two-step approach, as required under U.S. GAAP, and determined that a portion of its goodwill was impaired. As a result, in the second quarter of fiscal 2009, the Company recorded a non-cash charge of $2.34 billion. In addition, the Company also recorded a charge of $4.1 million for the write-off of certain intangible assets and recorded such charge within cost of revenues in fiscal 2009. These non-cash charges are included in the non-GAAP adjustments in the financial information presented in this release. A further discussion of our non-GAAP fiscal 2009 results and guidance is included in the attachment to this press release.

As of September 26, 2009, total backlog for all products was $323.1 million.

"We are pleased with our performance for the fourth quarter of fiscal 2009," said Rob Cascella, President and Chief Executive Officer. "We not only exceeded our revenue guidance, but we once again exceeded our guidance for EPS. Although the economic environment continues to impact our capital equipment sales, we are very pleased with the continued performance of our Diagnostics and GYN Surgical segments, which performed at or above our expectations for both the fourth quarter and full year. Fiscal 2009 was a year of execution - we operated Th
'/>"/>

SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "12th Annual ... Production" report to their offering. ... Biopharmaceutical Manufacturing Capacity and Production is the most ... organizations, current and projected future capacity and production. ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Findings indicate early non-responders unlikely to subsequently,respond, ... benefit,from earlier change in treatment strategy, COLORADO ... data presented at the 2007 International Congress ... be assessed earlier than is presently thought, ...
... Average of More Than Two Hours Per ... 2007 /PRNewswire/ --,Adding the once daily, investigational ... to,Parkinson's patients' existing levodopa (L-dopa) therapy,significantly reduced ... activities for a longer period of time. ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
(Date:8/29/2015)... ... 2015 , ... Rio Salado College President Chris Bustamante announced on ... of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado for the ... and impact through innovative technologies and strategies. , “I am very proud to be ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... 29, 2015 , ... Brands like Toppik , Eau Thermale Avene and ... “Before, a threshold of $49.00 was required to qualify for free standard shipping,” said ... standard shipping for customers regardless of the item’s selling price.” , With competitive pricing ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining ... County Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage ... their outpatient wound center. , Transitioning wound care management providers can be ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... that the Bihar Government would do all that it ... the state //, addressing a HIV/AIDS workshop, organized by ... Control Organization (NACO). ,Expressing concern over the ... the Minster highlighted the need for concerted efforts in ...
... take a deep breath, immediately exhale forcefully and then ... before takeoff. // ,That is the advice ... German initials BVDP), which said the technique relaxes muscles ... ,BVDP chairwoman Christa Roth-Sackenheim advised affected persons to refrain ...
... which are used for calming the nervous, can ... older people. // ,Substances like diphenhydramine, ... create this paradox, says Ursula Sellerberg, spokeswoman for ... in Berlin. ,Diazepam, the main ingredient ...
... study many Americans are affected by insomnia, not able to get ... to sleep aids that will act fast and put them to ... "cure," however, shouldn't be the first course of action, says a ... the market, doctors tend to rely upon them because samples are ...
... Organization is beginning a five-day nationwide polio immunization campaign in ... children, below the age of five. // ,The ... said, "In fact, we are seeing that the number of ... even feel that in the North of the country which ...
... A research team from Georgia Institute of Technology has ... triposphate (ATP) release and its role in cystic fibrosis. ... micro- and nano-electrodes to the tip of an atomic ... simultaneously monitor topography along with electrochemical activity at the ...
Cached Medicine News:Health News:Sleep Aids Are Not The Best Option For Insomniacs 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3
Colloidal Gold Conjugated, Protein A - 12 OD...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: